Related Experiment Video
Updated: Jul 1, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Diabetes and Coronary Intervention: Special Considerations for Antithrombotic Therapy
R. Scott Wright1, Gregory W. Barsness
1*Mayo Medical School, Division of Cardiology and The Mayo Physician Alliance for Clinical Trials, Mayo Clinic and Foundation, Stabile 5, 150 Third Street SW, Rochester, MN 55902, USA. wright.scott@mayo.edu
Insights
Diabetic patients have advanced coronary artery disease and face unique challenges during percutaneous coronary intervention (PCI). Potent antithrombotic therapies improve PCI safety and effectiveness in this high-risk group.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a growing concern, linked to advanced coronary artery disease.
- Diabetic patients present a prothrombotic state, complicating interventional cardiology procedures.
- Percutaneous coronary intervention (PCI) in diabetics requires careful management due to increased cardiovascular risk.
Purpose of the Study:
- To review antithrombotic therapy options for diabetic patients undergoing PCI.
- To summarize current data on heparin, glycoprotein IIb/IIIa inhibitors, and oral antiplatelet agents in this population.
Main Methods:
- Literature review of studies on antithrombotic agents in diabetic patients undergoing PCI.
- Analysis of data on unfractionated heparin, low molecular weight heparin, intravenous glycoprotein IIb/IIIa blockers, and oral antiplatelet agents.
Main Results:
- Antithrombotic therapies have enhanced PCI safety and effectiveness in diabetic patients.
- Specific agents like heparins and glycoprotein IIb/IIIa blockers are crucial for managing thrombotic risk.
- Oral antiplatelet agents play a key role in long-term management post-PCI.
Conclusions:
- Effective antithrombotic strategies are vital for successful PCI in diabetic patients.
- The choice of antithrombotic therapy should be tailored to individual patient risk profiles.
- Continued research into optimal antithrombotic regimens for diabetics undergoing PCI is warranted.
Abstract:
Diabetes mellitus is an increasing problem in the Western world and is associated with a more advanced state of coronary artery disease than that observed in non-diabetic patients. Diabetes mellitus is a prothrombotic state and poses some unique challenges to the interventional cardiologist. The development of more potent antithrombotic therapies has improved the safety and effectiveness of percutaneous coronary intervention (PCI), particularly in high-risk groups such as diabetic patients. This article summarizes the available data on the use of heparins (unfractionated and low molecular weight), intravenous glycoprotein IIb/IIIa blockers, and oral antiplatelet agents in diabetic patients undergoing PCI.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

